Drug Development

Prometic expands sites for PBI-1402 trials for anemia

Published in Clinical Trials Week, October 16th, 2006

Prometic Life Sciences Inc. (TSX) announced that the board of directors has approved plans to expand its PBI-1402 phase Ib/II clinical trial to multiple sites in Canada and Europe.

PBI-1402 is an orally active drug targeting anemia. The company will also initiate PBI-1393 clinical trials for advanced cervical cancer.

The first (GLP) toxicology studies of PBI-1393 in rats and dogs have been completed. Preliminary analysis of the results indicates that PBI-1393 has a promising safety profile devoid of the severe toxicity displayed by other immunostimulants. While additional study will be undertaken to ensure the safety of PBI-1393, the green light was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2006-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry